In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
News|Podcasts|October 2, 2026
ACT Brief: Proactive Trial Risk Management, Federal Infrastructure Modernization, Pediatric Heart Disease Treatment
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part five of her interview , Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive. By enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled, AI moves from problem-solving after failures to prevention through early scenario modeling and feasibility validation. The HHS Advanced Research Projects Agency for Health launched the SURPASS program alongside three complementary initiatives to modernize trial design and operations , addressing the reality that clinical development takes over a decade on average and costs up to $2 billion. SURPASS combines adaptive platform design, real-time analytics, and operational automation, while companion programs expand site capacity through AI-enabled activation, build nationwide data infrastructure for regulatory-grade access, and give patients tools to contribute real-world data.- The
FDA approved an expanded indication for Camzyos for adults and pediatric patients weighing 30 kg (66 lbs) or more with symptomatic heart obstruction disease, marking the first disease-targeted therapy approved in this pediatric population and the broadest indication of any cardiac myosin inhibitor. The Phase III Scout-HCM trial enrolled 44 adolescents and showed the therapy reduced obstruction measurements by 48 millimeters compared with just 1.8 millimeters for placebo, with no patients experiencing dangerous heart function decline.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
4
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
5